Novartis Pursuing Trileptal Pediatric Monotherapy Indication
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis is in discussions with FDA over the proper course to obtain a pediatric monotherapy indication for its antiepileptic Trileptal. FDA initially turned down the indication due to a lack of data on the most effective dose for use in children, review documents indicate.